February was a crazy month for investors; consequently, the landscape of best-performing exchange-traded funds expanded from primarily biotech and emerging-market ETFs in January to several other spaces for this edition of the best ETFs of the month. In February, the fortitude of those with generally bullish outlooks was tested as the Dow Jones Industrial Average made historic 1,000-plus point drops twice in less than two weeks.

Meanwhile, the S&P 500 is down more than 4% on the month. The turmoil is mostly attributed to anticipation of a rise in interest rates based on expectations of inflation in the months ahead. But outside of these struggles, some ETFs still managed to maintain impressive performances, while others managed to step up and replace old champions. In no particular order, here are the best ETFs of February, excluding leveraged funds and exchange-traded notes. Among the best ETFs of February were several retail-based ETFs.

Notably, the ProShares Long Online/Short Stores ETF (NYSEARCA:CLIX) manged to stand out from the crowd, as it has significantly outperformed the S&P 500 in 2018 so far. This recently founded ProShares ETF is distinct in that it has a multifaceted strategy that aims to take full advantage of the death of traditional retail while also focusing on the rise of internet retailers.

The CLIX achieves this by shorting traditional retail stocks and simultaneously holding online retailers with significant growth. As such, its holdings are constantly varying. Last month, the Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) made it on the list of best-performing ETFs and it continued its success in February with an impressive 20% advantage over the S&P. For those who are unfamiliar with CNCR, it’s a biotech ETF that emphasizes companies that are involved with cancer research and treatment.

More specifically, CNCR’s holdings must have cancer immunotherapy drugs that are approved by the FDA or EMA, are in human testing stages, are about to enter human testing stages and/or are involved with other companies that focus on immunotherapy. This includes companies like Aduro BioTech Inc (NASDAQ:ADRO) and AstraZeneca plc (ADR) (NYSE:AZN), which are among its top 10 holdings.

Although some new names made the list of best ETFs of February, Brazilian emerging market ETFs like Franklin FTSE Brazil ETF (NYSEARCA:FLBR) still performed exceptionally well this month. The FLBR follows the FTSE Brazil Capped Index, which emphasizes the most notable large- and mid-cap companies in the country. Although investing in emerging markets like Brazil carries significant risks, top holdings like iron producer Vale SA (ADR) (NYSE:VALE) and brewing company Ambev SA (ADR) (NYSE:ABEV) give investors access to tons of growth potential in a less familiar marketplace.

Global X Social Media ETF (NASDAQ:SOCL) does exactly as its name suggests — it gives investors exposure to social media companies from across the world. As such, it isn’t your run-of-the-mill tech ETF. And the fact that it has outpaced the S&P 500 places it among the best ETFs of 2018 so far. The SOCL ETF does hold U.S.

Twitter Inc (NYSE:TWTR) and Snap Inc (NYSE:SNAP), but it also holds international social media stocks like Russian internet technology company Yandex NV (NASDAQ:YNDX) and Chinese internet-based holding company Tencent Holdings Ltd (OTCMKTS:TCEHY). As with last month, another Brazilian-based ETF — iShares MSCI Brazil Index (ETF) (NYSEARCA:EWZ) — managed to out-do the competition and it remains one of the best ETFs of 2018 so far.

This ETF isn’t significantly different from the FLBR, but as emphasized on last month’s list, EWZ is more focused — it has less holdings — and it has a significantly longer track record of success than relative newcomer FLBR. The Amplify Online Retail ETF (NASDAQ:IBUY) is another retail ETF that has managed to beat the competition at the start of the year and become one of the best-performing ETFs. Although many biotech ETFs were among the best performing last month, many tech/internet-based ETFs have manged to hold strong through February’s volatility.

Although it didn’t make an appearance on last month’s list, Russia was a notable emerging market in February, as seen in the standout performance in the iShares MSCI iShares MSCI Russia ETF (NYSEARCA:ERUS). While U.S. stocks were generally struggling to hold their ground, the ERUS manged to gain a 12% lead over the S&P.